Exact Mass: 335.06308240000004
Exact Mass Matches: 335.06308240000004
Found 58 metabolites which its exact mass value is equals to given mass value 335.06308240000004,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Dihydroneopterin phosphate
C9H14N5O7P (335.06308240000004)
Dihydroneopterin phosphate is involved in the folate biosynthesis pathway. Dihydroneopterin phosphate is produced from 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine. triphosphate by [E3.6.1.-]. Dihydroneopterin phosphate is then converted to Dihydroneopterin by [E3.6.1.-]. Dihydroneopterin phosphate is involved in the folate biosynthesis pathway. Dihydroneopterin phosphate is produced from 2-Amino-4-hydroxy-6-(erythro-1,2,3-trihydroxypropyl)dihydropteridine
sulfanitran
C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides
Flamprop-methyl
C17H15ClFNO3 (335.07244420000006)
isoxicam
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
2-Methyl-N-(5-methyl-3-isoxazolyl)-1,1,4-trioxo-3H-1$l^{6},2-benzothiazine-3-carboxamide
(Z)-3-Amino-3-(4-aminophenylthio)-2-(2-(trifluoromethyl)phenyl)acrylonitrile
Progabide acid
C17H15ClFNO3 (335.07244420000006)
D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
isoxicam
A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome. C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
beta-Nicotinamide D-ribonucleotide
4-(4-chloro-3,5-dimethylphenoxy)-N-hydroxy-3-nitrobenzenecarboximidamide
6-(p-Toluidino)-2-naphthalenesulfonic acid sodium salt
6-FLUORO-2-(3-(TRIFLUOROMETHYL)PHENYL)QUINOLINE-4-CARBOXYLIC ACID
8-FLUORO-2-(3-(TRIFLUOROMETHYL)PHENYL)QUINOLINE-4-CARBOXYLIC ACID
Acridine,6-chloro-2-methoxy-9-phenoxy-
C20H14ClNO2 (335.07130140000004)
SL-327
SL327 inhibits MEK1 and MEK2, with IC50 values of 180 nM and 220 nM, respectively.
1-(4-cyanophenyl)-5-(4-methylsulfanylphenyl)pyrazole-3-carboxylic acid
C18H13N3O2S (335.07284380000004)
3-carboxy-5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid
5-Bromo-1-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole
chlordiazepoxide hydrochloride
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
sulfachrysoidine
C13H13N5O4S (335.0688218000001)
C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent
N-(1,1-dioxo-3-thiolanyl)-N-(thiophen-2-ylmethyl)benzamide
1-(1,3-Benzodioxol-5-ylmethylthio)-[1,2,4]triazolo[4,3-a]quinoline
C18H13N3O2S (335.07284380000004)
[(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
Nicotinamide ribotide
Nicotinamide ribotide (NMN) (CAS: 1094-61-7) is an important intermediate metabolite in the nicotinate and nicotinamide metabolism pathway. Mammals predominantly use nicotinamide rather than nicotinic acid as a precursor for NAD biosynthesis. Instead of the deamidation into nicotinic acid, nicotinamide is directly converted into NMN by nicotinamide phosphoribosyltransferase (NAMPT, EC 2.4.2.12). The enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1), which is a member of the nucleotidyltransferase alpha/beta-phosphodiesterase superfamily, catalyzes the reaction NMN + ATP <=> nicotinamide adenine dinucleotide (NAD) + PPi, representing the final step in the biosynthesis of NAD. NAD is a molecule that plays a fundamental role as a cofactor in cellular redox reactions. Thus NMN is an important metabolite for the maintenance of normal NAD biosynthesis. Circulating NMN levels may play an important role in regulating cell function in physiological and pathophysiological conditions (PMID: 15078171, 17983582). Nicotinamide ribotide (NMN) is an important intermediate metabolite in the nicotinate and nicotinamide metabolism pathway. Mammals predominantly use nicotinamide rather than nicotinic acid as a precursor for NAD biosynthesis. Instead of the deamidation to nicotinic acid, nicotinamide is directly converted to NMN by nicotinamide phosphoribosyltransferase (NAMPT, EC 2.4.2.12). The enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1), a member of the nucleotidyltransferase alpha/beta-phosphodiesterase superfamily, catalyzes the reaction NMN + ATP = Nicotinamide adenine dinucleotide (NAD) + PPi, representing the final step in the biosynthesis of NAD, a molecule playing a fundamental role as a cofactor in cellular redox reactions. Thus NMN is an important metabolite for the maintenance of normal NAD biosynthesis, and circulating NMN levels may play an important role in regulating cell function in physiological and pathophysiological conditions. (PMID: 15078171, 17983582) [HMDB]
S-nitrosoglutathione(1-)
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors > D026403 - S-Nitrosothiols D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002317 - Cardiovascular Agents > D020030 - Nitric Oxide Donors D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000890 - Anti-Infective Agents D020011 - Protective Agents
2-Methyl-N-(5-methyl-3-isoxazolyl)-1,1,4-trioxo-3H-1$l^{6},2-benzothiazine-3-carboxamide
3-[2-(4-Aminoanilino)-4-thiazolyl]-1-benzopyran-2-one
C18H13N3O2S (335.07284380000004)
3-(4-Methylphenyl)-5-oxo-8-thiazolo[2,3-b]quinazolinecarboxamide
C18H13N3O2S (335.07284380000004)
[(2R,3S,4R,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
[7-[(3-Cyanophenyl)sulfonylamino]-4-methylindol-3-ylidene]methylideneazanide
C17H11N4O2S- (335.06026860000003)
(5s,10r)-9-thia-11,15,20-triazaheptacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0⁵,²⁰.0¹⁷,²¹]docosa-1,7,11,14(21),16-pentaene-6,13-dione
C18H13N3O2S (335.07284380000004)
(3s)-9-thia-11,15,20-triazahexacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0¹⁷,²¹]docosa-1(20),2(12),4,7,14(21),16-hexaene-6,13-dione
C18H13N3O2S (335.07284380000004)
(2s)-2-[(2r)-6-(carboxymethyl)-4-hydroxy-5,7-dioxo-2h,3h-furo[2,3-f]isoindol-2-yl]propanoic acid
C15H13NO8 (335.06411380000003)
(3r,5s,10r)-9-thia-11,15,20-triazaheptacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0⁵,²⁰.0¹⁷,²¹]docosa-1,7,11,14(21),16-pentaene-6,13-dione
C18H13N3O2S (335.07284380000004)
(3r)-9-thia-11,15,20-triazaheptacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0⁵,²⁰.0¹⁷,²¹]docosa-1,7,11,14(21),16-pentaene-6,13-dione
C18H13N3O2S (335.07284380000004)
2,3-dihydroxy-3-(4-hydroxy-2-imino-7,8-dihydro-1h-pteridin-6-yl)propoxyphosphonic acid
C9H14N5O7P (335.06308240000004)
2-[6-(carboxymethyl)-4-hydroxy-5,7-dioxo-2h,3h-furo[2,3-f]isoindol-2-yl]propanoic acid
C15H13NO8 (335.06411380000003)
(2r,3s)-2,3-dihydroxy-3-(4-hydroxy-2-imino-7,8-dihydro-1h-pteridin-6-yl)propoxyphosphonic acid
C9H14N5O7P (335.06308240000004)
(2r)-2-[(2s)-6-(carboxymethyl)-4-hydroxy-5,7-dioxo-2h,3h-furo[2,3-f]isoindol-2-yl]propanoic acid
C15H13NO8 (335.06411380000003)
(3r,5s,10s)-9-thia-11,15,20-triazaheptacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0⁵,²⁰.0¹⁷,²¹]docosa-1,7,11,14(21),16-pentaene-6,13-dione
C18H13N3O2S (335.07284380000004)
9-thia-11,15,20-triazahexacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0¹⁷,²¹]docosa-1(20),2(12),4,7,14(21),16-hexaene-6,13-dione
C18H13N3O2S (335.07284380000004)
(3s,10s)-9-thia-11,15,20-triazahexacyclo[12.6.1.1³,¹⁰.0²,¹².0³,⁸.0¹⁷,²¹]docosa-1(20),2(12),4,7,14(21),16-hexaene-6,13-dione
C18H13N3O2S (335.07284380000004)